Amgen and Novartis Join Atlas Venture Fund IX As Corporate Strategic Partners

Amgen and Novartis Join Atlas Venture Fund IX As Corporate Strategic Partners

CAMBRIDGE, Mass. – May 16, 2013 – Atlas Venture is pleased to announce that it has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures  and Novartis are new limited partners. 

The intent of these relationships is to provide Amgen and Novartis with strategic proximity to Atlas Venture's startup formation activities around innovative, potentially high impact medicines, and catalyze future collaborations around translational research across Atlas Venture's early stage portfolio.  Amgen and Novartis bring their deep knowledge in pharmaceutical R&D with Atlas Venture's focus on creating and building new biomedical startups with experienced entrepreneurs. 

These CSP relationships are further momentum around the increasingly collaborative early stage biotech ecosystem, bringing venture and pharma interests together.  Under the agreements, Atlas Venture intends to explore a range of new opportunities with Amgen and Novartis including co-creation of life sciences startups, formation of asset-centric development projects, and helping translate discoveries from ongoing academic collaborations, among others.

"Amgen is very excited to partner with Atlas Venture, one of a small number of venture capital groups that truly focuses on creating value by translating groundbreaking science into new companies," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

"This partnership will enable us to help some of the best and the brightest academic scientists and biotech entrepreneurs get their ideas off the ground," said Mark C. Fishman, President of Novartis Institutes for BioMedical Research (NIBR). "We look forward to working with the Atlas team to build young start-ups that will hopefully one day lead to the development of new medicines for patients in need."

The agreements do not constitute exclusivity or any commitment of Amgen or Novartis to pursue opportunities. Atlas Venture maintains full authority over funding strategy and investment decisions.  This "open market" principle is an important element of these CSP relationships, which are designed to facilitate the partners exploring opportunities of mutual strategic interest.  Atlas IX is expected to create and/or fund more than fifteen new biotech companies, and we anticipate these new CSP relationships will be integral part of facilitating their launch and progression.    

About Atlas Venture

Atlas Venture is a leading early-stage venture capital firm that invests in technology and life sciences companies. Since inception in 1980, we have helped build over 350 companies. Atlas Venture is currently investing from its ninth fund. For more information, please visit www.atlasventure.com.

Suggested Articles

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.